UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With ~8000 people in approximately 40 countries, the company generated revenue of € 3.876 billion in 2015. UCB is listed on Euronext Brussels (symbol: UCB). We partner and create super-networks with world-leading scientists and clinicians in academic institutions, pharmaceutical companies and other organizations who share our goals. At UCB, we are inspired by patients and driven by science in our commitment to support patients. UCB has Research and Development Centers of Excellence in Europe, the U.S. and Asia. • Strong in-house capabilities and control of key steps in the value chain • Extensive experience in preclinical and clinical development, regulatory affairs and managing international alliances • Research organ